Celcuity to Present Key Gedatolisib Data at ESMO 2026

Event summary

Celcuity will present four data sets at ESMO 2026, including a late-breaking oral presentation on VIKTORIA-1 trial results.
Presentations cover gedatolisib in HR+/HER2- advanced breast cancer and mCRPC indications.
Abstracts will be published online on October 19, 2026, with poster sessions starting October 23, 2026.
VIKTORIA-1 data focuses on PIK3CA mutant-type cohort and comparative analyses of PIK3CA wild-type cohort.

The big picture

Celcuity's ESMO presentations come as the company seeks to expand the clinical utility of its FDA-approved gedatolisib (REVTORPYK) beyond PIK3CA-mutant breast cancer. The data could influence treatment paradigms for HR+/HER2- advanced breast cancer and mCRPC, where PI3K/mTOR inhibitors represent a growing therapeutic class. Success in these indications would position Celcuity against established players like Novartis and Pfizer in the targeted oncology space.

What we're watching

Clinical Efficacy: How VIKTORIA-1 data will position gedatolisib against existing HR+/HER2- breast cancer treatments.
Regulatory Pathway: Whether positive ESMO data could accelerate approvals for additional indications.
Market Differentiation: The pace at which Celcuity can establish gedatolisib as a differentiated therapy in the PI3K/mTOR inhibitor space.